뒤로
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.(02315.HK) 가격
02315.HK 주가 차트
BIOCYTOGEN-B (02315.HK)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
HK$39.72
-8.22%
$-3.56
장 종료: Jan 19, 16:00:00 HKT
아직 데이터 없음Earnings FAQ
02315.HK의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 02315.HK의 지난 분기 매출 실적은 어땠나요?
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.의 매출 추정치는 얼마인가요?
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.의 수익 품질 점수는 얼마인가요?
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.는 언제 수익을 보고하나요?
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.의 예상 수익은 얼마인가요?
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$43.28
시가
$43.28
일일 범위
$39 - $43.28
52주 범위
$7.07 - $39.72
거래량
2.3M
평균 거래량
689.4K
EPS(TTM)
0.37
배당수익률
--
시가총액
$4.2B
BIOCYTOGEN-B란 무엇인가요?
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing and currently employs 1,306 full-time employees. The company went IPO on 2022-09-01. The firm utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Company’s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The firm is also engaged in the provision of gene-editing services. The firm operates its businesses in the domestic market and overseas markets.